Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Feb. 7 '26)

Image
By G.M.

 


    Antimicrob Agents Chemother

  1. LLORENTE J, Sempere J, Llamosi M, Perez-Garcia C, et al
    Emergence of antibiotic-resistant pneumococcal serotypes causing invasive pneumococcal disease in children, Spain.
    Antimicrob Agents Chemother. 2025 Dec 31:e0153025. doi: 10.1128/aac.01530.
    PubMed         Abstract available


    J Infect Dis

  2. VILLAFUERTE D, Fall A, Akin E, Werner AP, et al
    Genomic Evolution of Influenza A Virus During the 2024-2025 Season, the Johns Hopkins Health System: Antigenic Drift Reduces Serum Neutralization.
    J Infect Dis. 2026 Feb 4:jiag069. doi: 10.1093.
    PubMed         Abstract available


    Pediatrics

  3. GAGO CM, Ruggiero CF, Gundewar A, Rose W, et al
    Parent Perspectives on the Interactive Role of Charitable and Federal Nutrition Assistance.
    Pediatrics. 2026 Jan 6:e2025072664. doi: 10.1542/peds.2025-072664.
    PubMed         Abstract available

  4. SALTHOUSE AL, Tannis A, Rutkowski RE, Weinberg GA, et al
    Hospitalization Outcomes of Full-Term and Premature Children Aged Less Than 2 Years Hospitalized With RSV.
    Pediatrics. 2026 Jan 8:e2025072578. doi: 10.1542/peds.2025-072578.
    PubMed         Abstract available


    PLoS One

  5. BOU-HAMAD I
    Understanding consumer behavior in Lebanon's polycrisis: The role of ethnocentrism, coping ability, and socioeconomic status.
    PLoS One. 2026;21:e0341265.
    PubMed         Abstract available

  6. MCMILLAN M, Beazley R, Vasilunas N, Sullivan TR, et al
    Children and adolescents: Respiratory infection and long-term effects longitudinal study (CARE Study): Study protocol.
    PLoS One. 2026;21:e0341566.
    PubMed         Abstract available

  7. CHURIWAL M, Tompkins K, Streeter G, Litel C, et al
    Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort.
    PLoS One. 2026;21:e0313467.
    PubMed         Abstract available

  8. MERKLEY E, Loewen PJ
    Economic shock and the erosion of COVID-19 precautionary behavior in Canada during the early pandemic.
    PLoS One. 2026;21:e0340685.
    PubMed         Abstract available

  9. AHABWENKI R, Piloya T, Namiiro F, Muzeyi W, et al
    Impact of COVID-19 on New - onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda.
    PLoS One. 2026;21:e0341145.
    PubMed         Abstract available

  10. EDAE CK, Bedada AT, Teklemariam MD, Tolesa MB, et al
    A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia.
    PLoS One. 2026;21:e0340457.
    PubMed         Abstract available

  11. DINERO RE, Monti WB, Kmush BL
    Regional political climate's moderating role in the association between political conservatism and COVID-19 vaccine hesitancy in the United States.
    PLoS One. 2026;21:e0342063.
    PubMed         Abstract available

  12. WU X, Rai SN, Weber GF
    Model-free prognostication of non-linear time series.
    PLoS One. 2026;21:e0341777.
    PubMed         Abstract available

  13. KIM S, Kim K
    Combined association of socioeconomic status and type 2 diabetes with influenza vaccination in older adults: A cross-sectional analysis of the Korea National Health and Examination Survey (2019-2022).
    PLoS One. 2026;21:e0341831.
    PubMed         Abstract available

  14. BRAEYE T, Abrams S, Hens N
    Factors influencing SARS-CoV-2 IgG test sensitivity: A Bayesian analysis of seroconversion and seroreversion by time since infection, test, age and disease severity.
    PLoS One. 2026;21:e0328144.
    PubMed         Abstract available

  15. TRAKSEL R, Broen J, van Henten A, Konigs M, et al
    Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial.
    PLoS One. 2026;21:e0341126.
    PubMed         Abstract available

  16. MOI F, Nguyen VM, Archer R, Namalela T, et al
    The cost and cost drivers of delivering COVID-19 vaccines in low- and middle-income countries: a bottom-up costing study of rollouts in seven countries.
    PLoS One. 2026;21:e0341964.
    PubMed         Abstract available

  17. MAVROVOUNIOTIS ML
    Use of Kaplan-Meier and Cox regressions in the distribution of length of stay in animal shelters for pre-specified calendar periods: Definition, computation, and examples of dog length of stay in orange county California.
    PLoS One. 2026;21:e0342102.
    PubMed         Abstract available

  18. VAN'T HOFF ST, Helfrich G, Boerman S, Hardeman HA, et al
    Extended thrombotic prophylaxis in COVID-19 early discharge: A retrospective cohort study.
    PLoS One. 2026;21:e0340889.
    PubMed         Abstract available

  19. DO MH, Nguyen TT, Grote U
    Households' poverty and inequality after the COVID-19: Insights from panel data of face-to-face surveys in Southeast Asia.
    PLoS One. 2026;21:e0341648.
    PubMed         Abstract available

  20. KINDU M, Yenesew MA, Kassie GG
    Infection prevention practices and associated factors among healthcare professionals in West Gojjam Zone public Hospitals Northwest Ethiopia, 2023.
    PLoS One. 2026;21:e0338621.
    PubMed         Abstract available

  21. REID CN, Beckstead JW, Salinas-Miranda AA
    Exploring the influence of COVID-19 stress on mental health among international undergraduate and graduate students: A mixed-methods approach.
    PLoS One. 2026;21:e0336446.
    PubMed         Abstract available

  22. CHIKANYA ER, Chimbari MJ
    Assessing knowledge levels on coronavirus disease (COVID-19) among community members: The influence of community engagement efforts in Seke district, Zimbabwe: A cross-sectional study.
    PLoS One. 2026;21:e0342318.
    PubMed         Abstract available

  23. MIRANDA MF, Alvarez C, Earp J, Gurovich AN, et al
    Eccentric cycling is superior to standard rehabilitation for Post-ICU recovery in COVID-19 survivors.
    PLoS One. 2026;21:e0340965.
    PubMed         Abstract available

  24. ASSAAD M, Chamma N, Mateev M, Rizk R, et al
    Telehealth during and beyond the COVID-19 Pandemic: Evidence from licensed dietitians in an emerging economy.
    PLoS One. 2026;21:e0311330.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  25. WANG J, Tai W, Wang Z, Dai W, et al
    SARS-CoV-2 S assembly into virions facilitated by host ERM proteins.
    Proc Natl Acad Sci U S A. 2026;123:e2504517123.
    PubMed         Abstract available


    Vaccine

  26. WIWE EF, Jorgensen M, Brandt L, Talouzi N, et al
    Spike antibody levels and risk of SARS-CoV-2 reinfection: a two-year cohort study in previously infected adults.
    Vaccine. 2026;74:128194.
    PubMed         Abstract available

  27. ZHANG M, Huang S, Ruan C, Jiang Y, et al
    Anti-vaccination attitudes and behavioral intentions towards three recommended vaccinations among Chinese older adults with chronic diseases: A multicenter cross-sectional study.
    Vaccine. 2026;74:128191.
    PubMed         Abstract available

  28. RENNER TM, Agbayani G, Azizi H, Deschatelets L, et al
    Heterologous vs. homologous vaccine regimens: Sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted SARS-CoV-2 spike protein boost following an mRNA/LNP prime induces robust and balanced immune responses.
    Vaccine. 2026;74:128182.
    PubMed         Abstract available

  29. ALBY-LAURENT F, Ouedrani A, Jateau P, Strullu M, et al
    Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study.
    Vaccine. 2026 Jan 7:128130. doi: 10.1016/j.vaccine.2025.128130.
    PubMed         Abstract available

  30. HOBBS M, Marek L, Wiki J, Paynter J, et al
    Examining spatial variation and inequity in COVID-19 immunisation coverage in Aotearoa New Zealand: a nationwide geospatial study.
    Vaccine. 2026;74:128165.
    PubMed         Abstract available

  31. GIDUTHURI JG, Vengiau G, Vutliu V, Manineng C, et al
    Behavioural and social drivers of COVID-19 vaccination in Papua New Guinea: A cross-sectional study.
    Vaccine. 2026;74:128207.
    PubMed         Abstract available

  32. HERRAEZ CARRERA O, Gomez-Romero FJ, Marin Sanchez R, Fernandez Martin J, et al
    Impact of respiratory syncytial virus immunoprophylaxis on paediatric consultations: a time series study in Castilla-La Mancha, Spain (2022-2024).
    Vaccine. 2026;74:128229.
    PubMed         Abstract available

  33. MALLET A, Jaunay LB, Jaury P, Partouche H, et al
    Vaccine refusal during the COVID-19 pandemic: A qualitative study.
    Vaccine. 2026;74:128206.
    PubMed         Abstract available

  34. MADSEN AMR, Schaltz-Buchholzer F, Trebbien R, Roring R, et al
    Evaluating the non-specific effects of BCG vaccination on the immune system and serological response to influenza vaccination in the elderly: A randomised controlled trial.
    Vaccine. 2026;76:128305.
    PubMed         Abstract available

  35. KIM DH, Kim JC, Lee SH, Kim J, et al
    Efficacy of dual administration vaccine of recombinant Newcastle disease virus expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza and viscerotropic Velogenic Newcastle disease virus in broilers.
    Vaccine. 2026;76:128288.
    PubMed         Abstract available


    Virus Res

  36. LUO X, Liu H, Kuang H, Xie Y, et al
    Impacts of Delayed Influenza Vaccination on Clinical Outcomes in ICU-Admitted Patients with Influenza: A Retrospective Cohort Study.
    Virus Res. 2026 Feb 3:199700. doi: 10.1016/j.virusres.2026.199700.
    PubMed         Abstract available

  37. NAZKI S, Reine J, Kailath R, Gilbert S, et al
    Replication-incompetent viral vaccine vectors ChAdOx1 and MVA as tools for evaluating T-cell responses to naturally processed antigens in vitro.
    Virus Res. 2026;364:199691.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »